Topic

Articles

The acquisition builds on the companies' earlier collaboration to develop T-cell-based therapeutics.

Celgene to Acquire Juno Therapeutics in $9-Billion Deal

The acquisition strengthens Charles River Laboratories’ capabilities in the oncology and immunology therapeutic areas.

Charles River Laboratories Acquires KWS BioTest

The acquisition, valued at EUR 520 million (US$631 million), would expand Takeda’s late-stage pipeline in gastroenterology and would extend an already existing collaboration between the two companies.

Takeda to Acquire TiGenix

Mallinckrodt has agreed to acquire biopharmaceutical company Sucampo Pharmaceuticals for $18 per share, or a transaction value of approximately $1.2 billion.

Mallinckrodt to Acquire Sucampo Pharmaceuticals in $1.2-Billion Deal

Roche has agreed to acquire Ignyta, an oncology company specializing in precision medicines, in an all-cash transaction valued at $1.7 billion. 

Roche to Aquire Ignyta in $1.7-Billion Deal

Gilead Sciences will acquire Cell Design Labs to further cell-therapy research and development efforts.

Gilead Sciences and Kite to Acquire Cell Design Labs

The acquisition deepens Astellas’ involvement in the development of a pipeline of therapeutics focused on mitochondrial function.

Astellas Acquires Mitobridge in $450-Million Deal

The acquisition gives GE Healthcare access to a nanofiber-based platform purification technology that can offer improvements in biopharmaceutical productivity.

GE Healthcare Completes Acquisition of Bioprocessing Start-Up

Almac Group will acquire BioClin Laboratories to expand Almac’s analytical service offerings. 

Almac Group to Acquire BioClin Laboratories

The contract research organization (CRO) has acquired Xenometrics, a non-clinical CRO specializing in preclinical assessment of new drug candidates.

Mergers and Acquisitions